Objective: From the economic point of view, this study was to systematically assess the status quo on lung cancer screening in the world and to provide reference for further research and implementation of the programs, in China. Methods: PubMed, EMbase, The Cochrane Library,CNKI and Wanfang Data were searched to gather papers on studies related to economic evaluation regarding lung cancer screening worldwide, from the inception of studies to June 30(th), 2018. Basic characteristics, methods and main results were extracted. Quality of studies was assessed. Cost were converted to Chinese Yuan under the exchange rates from the World Bank. The ratio of incremental cost-effectiveness ratio (ICER) to local GDP per capita were calculated. Results: A total of 23 studies (only 1 randomized controlled trial) were included and the overall quality was accepted. 22 studies were from the developed countries. Nearly half of the studies (11 studies) took 55 years old as the starting age of the screening program. Smoking history was widely applied for the selection of criteria on target populations (18). Low-dose computed tomography (LDCT) was involved in every study used to evaluate the economic effectiveness. Annual (17) and once-life time (7) screening were more common frequencies. 22 studies reported ICERs for LDCT screening, compared to no screening, of which 17 were less than 3 times local GDP per capita, and were considered as cost-effectiveness, according to the WHO's recommendation. 15 and 7 studies reported ICERs for annual and once-life time screening, of which 12 and 7 studies were in favor the results of their cost-effectiveness, respectively. Additionally, the cost-effectiveness of once-lifetime screening was likely to be superior to the annual screening. Differences of cost-effectiveness among the subgroups, by starting age or by the smoking history, might exist. Conclusions: Based on the studies, evidence from the developed countries demonstrated that LDCT screening programs on lung cancer, implemented among populations selected by age and smoking history, generally appeared more cost-effective. Combined with the local situation of health resource, the findings could provide direction for less developed regions/countries lacking of local evidence. Low frequency of LDCT screening for lung cancer could be adopted when budget was limited. Data on starting ages, smoking history and other important components related to the strategy of screening programs, needs to be precisely evaluated under the situation of local population.
目的： 了解全球肺癌筛查的卫生经济学评价研究进展，为我国相关研究和筛查工作开展提供参考。 方法： 系统检索PubMed、EMbase、The Cochrane Library、中国知网及万方数据知识服务平台自建库至2018年6月30日间肺癌筛查卫生经济学研究相关文献，摘录其经济学评价方法及结果等信息，并进行质量评价。成本统一货币单位后计算增量成本效果比（ICER）后计算与当年当地人均GDP比值。 结果： 共纳入23项研究（1项基于人群随机对照试验，20项完全基于模型评价），整体质量较好；22项来自发达国家，11项筛查起始年龄为55岁，18项目标人群考虑了吸烟史；评价的筛查技术全部涉及低剂量螺旋CT（LDCT），筛查频率以每年1次（17项）和终生1次（7项）居多。22项研究可获得与未筛查相比的ICER，其中17项研究报道的ICER低于3倍当年当地人均GDP。各有15项和7项研究可获得每年1次和终生1次的ICER，其中各有12项和7项支持其经济有效，且终生1次略优于每年1次；不同筛查起始年龄和吸烟包年的经济有效性优劣差异不明显。 结论： 发达国家多开展基于模型LDCT肺癌筛查卫生经济学评价，并结合年龄和吸烟史进行高危人群选择，初步提示该方案经济有效；可为证据有限的欠发达地区提供参考，但实施需结合当地卫生资源现状；预算有限时低频次LDCT筛查更佳，而筛查起始年龄和吸烟史等细节确定需结合人群特征进行精准评价。.
Keywords: Economic evaluations; Mass screening; Neoplasm, lung; Systematic review.